Art. -Nr.: HY-111538

MAGL-IN-1

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.45%
CAS. Nr.: 2324160-91-8
Formel: C₂₂H₂₄FNO₃
Molecular Weight:369.43

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MAGL-IN-1 Chemical Structure

CAS. Nr.: 2324160-91-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 80 nM (MAGL)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Caov-3 cell line	IC₅₀	25 μM Compound: 23	Growth inhibition of human Caov3 cells after 96 hrs by celltiter-glo assay Growth inhibition of human Caov3 cells after 96 hrs by celltiter-glo assay	[PMID: 30715876]
HCT-116	IC₅₀	21 μM Compound: 23	Growth inhibition of human HCT116 cells after 96 hrs by celltiter-glo assay Growth inhibition of human HCT116 cells after 96 hrs by celltiter-glo assay	[PMID: 30715876]
HEK293	IC₅₀	>10 μM Compound: 23	Inhibition of human ABHD12 expressed in HEK293 cell homogenates pre-incubated for 30 mins in presence of [1,2,3-3H]2-OG by liquid scintillation spectroscopy Inhibition of human ABHD12 expressed in HEK293 cell homogenates pre-incubated for 30 mins in presence of [1,2,3-3H]2-OG by liquid scintillation spectroscopy	[PMID: 30715876]
HEK293	IC₅₀	>10 μM Compound: 23	Inhibition of human ABHD6 expressed in HEK293 cell homogenates pre-incubated for 30 mins in presence of [1,2,3-3H]2-OG by liquid scintillation spectroscopy Inhibition of human ABHD6 expressed in HEK293 cell homogenates pre-incubated for 30 mins in presence of [1,2,3-3H]2-OG by liquid scintillation spectroscopy	[PMID: 30715876]
MDA-MB-231	IC₅₀	7.9 μM Compound: 23	Growth inhibition of human MDA-MB-231 cells after 96 hrs by celltiter-glo assay Growth inhibition of human MDA-MB-231 cells after 96 hrs by celltiter-glo assay	[PMID: 30715876]
MRC5	IC₅₀	>100 μM Compound: 23	Growth inhibition of human MRC5 cells after 96 hrs by celltiter-glo assay Growth inhibition of human MRC5 cells after 96 hrs by celltiter-glo assay	[PMID: 30715876]
OVCAR-3	IC₅₀	57 μM Compound: 23	Growth inhibition of human OVCAR3 cells after 96 hrs by celltiter-glo assay Growth inhibition of human OVCAR3 cells after 96 hrs by celltiter-glo assay	[PMID: 30715876]
SK-OV-3	IC₅₀	15 μM Compound: 23	Growth inhibition of human SKOV3 cells after 96 hrs by celltiter-glo assay Growth inhibition of human SKOV3 cells after 96 hrs by celltiter-glo assay	[PMID: 30715876]

In Vitro

MAGL-IN-1 (compound 23) (0.02-200 μM; 96 h) produces an appreciable inhibition of cell viability in all the tested cancer cell lines, with IC₅₀s ranging from 7.9 to 57 μM^[1].
MAGL-IN-1 (0.125-1 μM; 30 min) competitively binds to MAGL with 4-nitrophenylacetate, with a K_i of 39 nM^[1].
MAGL-IN-1 (10 μM; 90 min) does not significantly inhibit CB1, CB2, FAAH, ABHD6 and ABHD12 activity at the concentration of 10 μM^[1].
MAGL-IN-1 (1 nM-100 μM; 15 min) inhibits [³H]2-oleoyl glycerol (2-OG) hydrolysis in a concentration dependent manner in U937 cells, with an IC₅₀ of 193 nM^[1].
MAGL-IN-1 (0.01-30 μM; 15 min) inhibits 2-OG hydrolysis in a concentration-dependent manner in mouse brain membrane preparations, with an IC₅₀ of 2.1 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

HCT116, MDA-MB-231, CAOV3, OVCAR3, SKOV3, and MRC5 cells
Concentration:

0.02-200 μM
Incubation Time:

96 hours
Result:

Inhibited the growth of human breast MDA-MB-231, colorectal HCT116, and ovarian CAOV3, OVCAR3, and SKOV3 cancer cells, with IC₅₀s of 7.9, 21, 25, 57, and 15 μM, respectively.
Was inactive against MRC5 (IC₅₀>100 μM).

In Vivo

MAGL (compound 23) (50 mg/kg; a single i.p.) increases the 2-AG level in plasma and brain, and does not alter anandamide (AEA), arachidonic acid and prostaglandin levels in plasma and brain of mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL6 mice, 8-10 weeks old^[1]
Dosage:

50 mg/kg
Administration:

Intraperitoneal injection; once
Result:

Increased 2-AG levels in the brain and plasma.

Chemical Information

CAS. Nr. 2324160-91-8
Appearance Solid
Molecular Weight 369.43
Formel C₂₂H₂₄FNO₃
Color White to off-white
SMILES

O=C(C1CCN(C(C2=CC(O)=CC=C2F)=O)CC1)C3=CC=C(C(C)C)C=C3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 Mar 16.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 62.5 mg/mL (169.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7069 mL

13.5344 mL

27.0687 mL

5 mM

0.5414 mL

2.7069 mL

5.4137 mL

10 mM

0.2707 mL

1.3534 mL

2.7069 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (5.63 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Granchi C, et al. Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor. J Med Chem. 2019 Feb 28;62(4):1932-1958. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7069 mL	13.5344 mL	27.0687 mL	67.6718 mL
	5 mM	0.5414 mL	2.7069 mL	5.4137 mL	13.5344 mL
	10 mM	0.2707 mL	1.3534 mL	2.7069 mL	6.7672 mL
	15 mM	0.1805 mL	0.9023 mL	1.8046 mL	4.5115 mL
	20 mM	0.1353 mL	0.6767 mL	1.3534 mL	3.3836 mL
	25 mM	0.1083 mL	0.5414 mL	1.0827 mL	2.7069 mL
	30 mM	0.0902 mL	0.4511 mL	0.9023 mL	2.2557 mL
	40 mM	0.0677 mL	0.3384 mL	0.6767 mL	1.6918 mL
	50 mM	0.0541 mL	0.2707 mL	0.5414 mL	1.3534 mL
	60 mM	0.0451 mL	0.2256 mL	0.4511 mL	1.1279 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8459 mL
	100 mM	0.0271 mL	0.1353 mL	0.2707 mL	0.6767 mL

Keywords

MAGL-IN-1

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MAGL-IN-1

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MAGL-IN-1

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MAGL-IN-1

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MAGL-IN-1

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MAGL-IN-1 Related Classifications

HY-111538 Related Classifications